Market Cap: $162.13M
IS
Innate Pharma S.A.
IPHA
NASDAQ (NASDAQ Global Select)USD
Market Cap: $162.13M
Innate Pharma Strengthens Position in Immunotherapy Development Innate Pharma SA, based in Marseille, France, announces its total shares outstanding and voting rights as of December 31, 2024, in compl…
Innate Pharma's Commitment to Cancer Immunotherapy Development Innate Pharma SA, a clinical-stage biotechnology firm based in Marseille, France, underscores its commitment to advancing cancer immunoth…
Innate Pharma Unveils Ambitious Growth Strategy Focused on Innovation and Collaboration Innate Pharma SA is charting a transformative path in oncology and autoimmune disease treatment with its newly u…
Innate Pharma Unveils Bold Growth Strategy Focused on Innovative Therapies Innate Pharma SA announces a robust growth strategy centered on enhancing innovation in immunotherapy, particularly through i…
Innovative Cancer Immunotherapy: Innate Pharma's Role in the Future of Treatment Innate Pharma SA, a biotechnology enterprise based in Marseille, France, is actively shaping the landscape of cancer tr…
Innate Pharma to Showcase Advancements in Cancer Immunotherapy at J.P. Morgan Healthcare Conference Innate Pharma SA, a clinical-stage biotechnology company headquartered in Marseille, France, is pois…
Innate Pharma Partners with IFLI to Advance Follicular Lymphoma Treatment Innate Pharma SA has announced a significant collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to enh…
Advancing Treatment Options for Follicular Lymphoma: Innate Pharma Partners with IFLI Innate Pharma SA has embarked on a significant collaboration with the Institute for Follicular Lymphoma Innovation…
Innate Pharma Charts Strategic Path with Upcoming Financial Calendar Innate Pharma SA, a clinical-stage biotechnology firm specializing in innovative immunotherapy for cancer treatment, releases its f…
Innovative Therapies at the Forefront of Innate Pharma’s Strategy Innate Pharma SA, a clinical-stage biotechnology firm based in Marseille, France, focuses on developing groundbreaking immunotherapies…